ArticleMedicine2025
No causal relationship between polyunsaturated fatty acids and inflammatory bowel disease: A Mendelian randomization study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disease, and dietary factors are associated with the onset and progression of IBD. The study aimed to investigate the causal association between some polyunsaturated fatty acids (PUFAs) and IBD, elucidating the nature of interactions occurring between them, and providing complementary guidance for clinical practice. Two-sample Mendelian randomization (MR) analysis was performed to elucidate the causal association between eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), docosahexaenoic acid (DHA), linoleic acid (LA), and arachidonic acid (ARA) and IBD. These PUFAs and IBD were considered the exposure and outcome, respectively. The R TwoSampleMR package was used to conduct the analysis. We employed the weighted median method, weighted mode model, random effects inverse-variance weighted model, and MR-Egger method and observed no causal relationship between EPA, DPA, DHA, ARA, and LA and IBD, Crohn's disease (CD), and ulcerative colitis (UC). Furthermore, in reverse MR analysis, in which IBD, CD, and UC were the exposures and EPA, DPA, DHA, ARA, and LA were the outcomes, we observed no causal effect of IBD, CD, and UC on the investigated PUFAs. Finally, through independent genome-wide association studies, we validated concordant null causal effects of all PUFAs on IBD. Using MR, we systematically assess the causal effects of specific n-3 and n-6 PUFAs on IBD risk. Our results suggest no causal relationship between specific PUFAs (EPA, DPA, DHA, LA, and ARA) and IBD. Therefore, routine PUFA supplementation is unlikely to benefit IBD management and that single-PUFA intervention strategies lack a sound biological basis. Future studies should incorporate ancestry-matched genetic datasets to enhance generalizability, employ multi-omics approaches to investigate PUFAs metabolic pathways, and explore gene-environment interactions in PUFAs metabolism to further elucidate their potential role in IBD pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.